Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $298
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman has maintained an 'Outperform' rating on Alnylam Pharmaceuticals and raised the price target from $275 to $298.
November 01, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reaffirmed its 'Outperform' rating for Alnylam Pharmaceuticals and increased the price target from $275 to $298, indicating a positive outlook.
The increase in price target from $275 to $298 by Raymond James suggests a positive outlook for Alnylam Pharmaceuticals, likely leading to a short-term increase in stock price. The 'Outperform' rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100